Sponsor: 
GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
Quadrivalent meningococcal conjugate vaccines

Registered for use in people aged ≥2 months.

MenACWY-CRM — quadrivalent meningococcal (serogroups A, C, W-135, Y)–CRM197 conjugate vaccine

Lyophilised powder containing serogroup A in a monodose vial with a pre-filled syringe or vial containing serogroups C, W-135 and Y in saline suspension.

Each 0.5 mL reconstituted dose contains:

  • 10 µg meningococcal polysaccharide serogroup A conjugated to 16.7–33.3 µg Corynebacterium diphtheriae CRM197 protein
  • 5 µg meningococcal polysaccharide serogroup C conjugated to 7.1–12.5 µg C. diphtheriae CRM197 protein
  • 5 µg meningococcal polysaccharide serogroup W-135 conjugated to 3.3–8.3 µg C. diphtheriae CRM197 protein
  • 5 µg meningococcal polysaccharide serogroup Y conjugated to 5.6–10 µg C. diphtheriae CRM197 protein

Also contains traces of:

  • sucrose
  • natural rubber

For full details, refer to the product information and consumer medicine information sheets for Menveo vaccine available on the TGA website.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018